MedTrace Logo

Retrospective Survey Evaluating the Effectiveness and Safety of Dual Inhibition Lipid-lowering in the Treatment of Dyslipidemia (Study P05171)(COMPLETED)

NCT00726856 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1200

Last updated 2022-02-16

No results posted yet for this study

Summary

This retrospective study evaluates the effectiveness and safety of ezetimibe plus statin or ezetimibe plus fenofibrate in dyslipidemic patients that were treated with these dual inhibition lipid lowering regimens as part of their normal standard of care. This study assesses the percentage of patients who achieve LDL-C target goals and also evaluates the patient compliance to treatment.

Conditions

Interventions

DRUG

Ezetimibe 10 mg plus statin or ezetimibe 10 mg plus fenofibrate

Ezetimibe 10 mg taken daily for 3 months

Sponsors & Collaborators

  • Organon and Co

    lead INDUSTRY

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-05-31
Primary Completion
2007-07-31
Completion
2007-07-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00726856 on ClinicalTrials.gov